---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003727"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:57:42.704705+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022

## Summary
- Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.
- R&D expenses $8.4M (vs $0.8M in Q3 2020); G&A $3.6M (vs $0.4M).
- PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
- TRACIr costimulatory bispecific candidate selection planned in 2022.
- Board strengthened with appointments of Ron Barrett (Ph.D.) and Alana McNulty.

## SEC filing metadata
- accession: 0000950170-21-003727
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/0000950170-21-003727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/janx-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003727
- JSON: https://secwatch.observer/filing/0000950170-21-003727.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.